Concomitant proton pump inhibitors and capecitabine-based chemoradiotherapy in rectal cancer: an ancillary study from the PRODIGE 23 trial.

Date publication

mars 2025

Journal

ESMO gastrointestinal oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BORG Christophe , Pr CONROY Thierry

Tous les auteurs :
Bridoux M, Aymes E, Conroy T, Gourgou S, Carnot A, Borg C, Le Deley MC, Turpin A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41646494

Résumé

Approximately one in five cancer patients use proton pump inhibitors (PPIs). In this work, we studied the effect of PPI co-medication during neoadjuvant chemoradiotherapy (NCRT) for locally advanced rectal cancer (LARC) based on the phase III PRODIGE 23 trial.

Mots clés

capecitabine-based chemoradiotherapy, neoadjuvant chemoradiotherapy, overall survival, proton pump inhibitors, recurrence-free survival

Référence

ESMO Gastrointest Oncol. 2025 03;7:100119